Related Experiment Video
Updated: May 6, 2026
Robotic Spleen-Preserving Distal Pancreatectomy: The Warshaw and Kimura Techniques
Published on: July 26, 2024
Selpercatinib-induced Acalculous Cholecystitis in an Elderly Patient with RET Fusion-positive Non-small Cell Lung
Takeru Ichikawa1, Ken Sato1, Yuto Sasano1
1Department of Respiratory Medicine, NHO Okayama Medical Center, Japan.
Abstract:
The effectiveness of selpercatinib against RET-fusion-positive non-small cell lung cancer (NSCLC) in geriatric patients is underreported. We report the case of an 84-year-old woman in whom reduced-dose selpercatinib elicited a significant tumor response in KIF5B-RET fusion-positive NSCLC. However, she developed acalculous cholecystitis, which led to the discontinuation of the drug. This is the first reported case of selpercatinib-induced acalculous cholecystitis in a patient. The report highlighted the potential efficacy of selpercatinib in elderly patients while underscoring the risk of severe adverse events and emphasizing monitoring and personalized dose management.
Insights
Reduced-dose selpercatinib showed efficacy in an 84-year-old with RET-fusion-positive non-small cell lung cancer (NSCLC). However, the patient developed acalculous cholecystitis, highlighting the need for careful monitoring in elderly patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Effectiveness of selpercatinib in geriatric patients with RET-fusion-positive non-small cell lung cancer (NSCLC) is not well-documented.
- Selpercatinib is a targeted therapy for RET-altered cancers.
Purpose of the Study:
- To report a case of reduced-dose selpercatinib treatment in an elderly patient with KIF5B-RET fusion-positive NSCLC.
- To highlight the efficacy and potential adverse events of selpercatinib in geriatric oncology.
Main Methods:
- Case report of an 84-year-old female patient with KIF5B-RET fusion-positive NSCLC.
- Administration of reduced-dose selpercatinib.
- Monitoring for treatment response and adverse events.
Main Results:
- The patient achieved a significant tumor response with reduced-dose selpercatinib.
- The patient developed acalculous cholecystitis, a previously unreported adverse event associated with selpercatinib.
- Discontinuation of selpercatinib was necessary due to the adverse event.
Conclusions:
- Selpercatinib demonstrates potential efficacy in elderly patients with RET-fusion-positive NSCLC.
- Acalculous cholecystitis is a potential severe adverse event of selpercatinib.
- Personalized dose management and vigilant monitoring are crucial for geriatric patients receiving selpercatinib.
